Quantum BioPharma changes management and grants bonuses, authorizes debt settlements for 2024.

Quantum BioPharma, a biopharmaceutical company specializing in innovative solutions for neurodegenerative and metabolic disorders, has announced management changes, with Donal Carroll as CFO, Nathan Coyle as Controller, and Jason Sawyer heading Finance and M&A. The company has cancelled options to purchase shares, granted restricted share units (RSUs), and authorized $450,000 bonuses per officer, to be paid in shares at $5.44 each. Debt settlements, involving officers Anthony Durkacz, Zeeshan Saeed, and Donal Carroll, are planned for September 2024.

August 24, 2024
4 Articles

Further Reading